What is Trelagliptin?

Trelagliptin (Trelagliptin) inhibits dipeptidyl peptidase-4 enzyme and increases GLP-1 to treat type 2 diabetes. In addition to its insulin secretagogue effect, it improves insulin resistance. Takeda Pharmaceutical Company approved it for use in Japan as Zafatek tablets in March 2015. As a once-weekly medication, it enhances patient compliance with treatment regimens more than other previously approved gliptins. Trelagliptin shows a high safety profile in patients with end-stage renal disease or even renal impairment.

Trelagliptin has been repositioned as a potential treatment for metabolic syndrome with multiple pharmacological effects and as a drug has multifaceted therapeutic effects that can reduce treatment costs. Additionally, repositioning trotagliptin for neurodegenerative diseases is suggested based on improving insulin resistance in the brain. Trelagliptin is a well-tolerated drug, administered less frequently, and adverse events are not serious. Clinical trials of trolagliptin have proven that it can effectively control blood sugar and plasma concentration of glycated hemoglobin in patients with type 2 diabetes.

The original drug of trotagliptin has not yet received relevant approval for marketing in China, so it cannot be covered by medical insurance. Currently, the price of trotagliptin original drug, specification 50mg*20 tablets per box, which is currently on the market overseas, may be around RMB 1,000 (the price may fluctuate due to exchange rates). There are also generic Trelagliptin drugs produced in other countries, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 100mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan per box (the price may fluctuate due to exchange rates). For more drug information and specific prices, please consult Yaode Medical Consultant.